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Abstract The completion of the Human Genome Project
resulted in discovery of many unknown novel genes. This
feat paved the way for the future development of novel
therapeutics for the treatment of human disease based on
novel biological functions and pathways. Towards this aim,
we undertook a bioinformatics analysis of in-house
microarray data derived from puriﬁed hematopoietic stem
cell populations. This effort led to the discovery of HSS1
(Hematopoietic Signal peptide-containing Secreted 1) and
its splice variant HSM1 (Hematopoietic Signal peptide-
containing Membrane domain-containing 1). HSS1 gene is
evolutionarily conserved across species, phyla and even
kingdoms, including mammals, invertebrates and plants.
Structural analysis showed no homology between HSS1
and known proteins or known protein domains, indicating
that it was a truly novel protein. Interestingly, the human
HSS1 (hHSS1) gene is located at chromosome 19q13.33, a
genomic region implicated in various cancers, including
malignant glioma. Stable expression of hHSS1 in glioma-
derived A172 and U87 cell lines greatly reduced their
proliferation rates compared to mock-transfected cells.
hHSS1 expression signiﬁcantly affected the malignant
phenotype of U87 cells both in vitro and in vivo. Further,
preliminary immunohistochemical analysis revealed an
increase in hHSS1/HSM1 immunoreactivity in two out of
four high-grade astrocytomas (glioblastoma multiforme,
WHO IV) as compared to low expression in all four low-
grade diffuse astrocytomas (WHO grade II). High-expres-
sion of hHSS1 in high-grade gliomas was further supported
by microarray data, which indicated that mesenchymal
subclass gliomas exclusively up-regulated hHSS1. Our
data reveal that HSS1 is a truly novel protein deﬁning a
new class of secreted factors, and that it may have an
important role in cancer, particularly glioma.
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Introduction
The completion of the Human Genome Project marked a
new era in our understanding of molecular genomics [1, 2].
With this remarkable feat, previously unknown and
uncharacterized proteins were revealed. The initial hope
was that perhaps hidden within the vastness of the human
genome were ‘‘truly novel proteins’’ with concomitant
novel functions in biology. A ‘‘truly novel protein’’ is
deﬁned as one which has no known counterparts—that is,
not just a newly-found member of a known protein family,
but a novel protein that deﬁnes a new protein class or
family [3]. The process of identifying and characterizing
novel proteins deﬁning a new protein class further opens up
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and pathways. This unveiling, in turn, could lead to sig-
niﬁcant progress in the treatment of human disease by
deﬁning new therapeutics and novel molecular targets.
In this paper, we provide the initial physical and func-
tional characterization of a novel protein that deﬁnes a new
protein class, designated as HSS1 (Hematopoietic Signal
peptide-containing Secreted 1). HSS1 and its membrane-
bound splice variant, HSM1 (Hematopoietic Signal pep-
tide-containing Membrane domain-containing 1), form the
ﬁrst members of a novel protein class or family in that
these proteins have no homology to any known proteins or
any known protein domains. Given the novelty of HSS1,
the elucidation of its function may provide insights into
previously unknown biological functions.
The discovery of HSS1 started with a search for novel
secreted proteins differentially expressed in hematopoietic
stem cells (HSCs), implying a possible role in stem cell
biology. We analyzed the gene expression proﬁles of three
highly puriﬁed populations of murine HSCs [4]. This
analysis led to the discovery of both mouse and human
homologs of HSS1. But since HSS1 is a novel gene/protein
that deﬁnes a novel protein class, no structural clues to its
function were available. The only apparent functional clue
was the gene locus of HSS1. Interestingly the gene related
to human HSS1 (hHSS1) maps to 19q13.33, a genomic site
of putative but largely uncharacterized suppressor(s) of
glioma and other cancers [5, 6]. This observation led us to
investigate a possible role for hHSS1 in glioma malig-
nancy. Thus, in this study we report the identiﬁcation and
characterization of a novel protein deﬁning a new protein
class, HSS1, as well as provide insight regarding its
functional role in glioma tumor biology.
Materials and methods
Isolation of HSS1 cDNA
The murine form of HSS1 (mHSS1) was isolated via PCR
from a lineage-negative mouse bone marrow cDNA library
[7]. The human form of HSS1 (hHSS1) was isolated from a
cDNA human testis library (Human MTC Multiple Tissue
cDNAPanelII,Clontech).Primerswerebaseduponpredicted
gene sequences and PCR products were sequenced to conﬁrm
the DNA sequence of both human and mouse HSS1 genes.
Cell culture and hHSS1 expression vector construct
Human embryonic kidney 293T and A172 glioma cell lines
(ATCC, Manassas, VA, USA) were cultured in DMEM
supplemented with 10% FBS. The human U87 glioma cell
line (ATCC HTB-14) was maintained in alpha-MEM
supplemented with 10% FBS, non-essential amino acids,
sodium pyruvate and sodium bicarbonate. The pTT3-
hHSS1 expression construct was kindly provided by Dr W.
French Anderson. The hHSS1 cDNA was subcloned from
pTT3 vector into the EcoRI and HindIII sites of pcDNA.3.1
mammalian expression vector (Invitrogen, Carlsbad, CA,
USA). The construct had a 6-His tag in-frame fused at the
C-terminal of hHSS1 gene. The resultant construct
pCDNA3.1-hHSS1 was veriﬁed by sequencing analysis.
Transient transfection and immunoblotting
Supernatants containing the hHSS1 protein were produced
by transient transfection of 293T cells harvested after 48 h
post-transfection using the Calcium Phosphate Transfection
kit (Invitrogen) and 4 lg of plasmid DNA puriﬁed with a
Qiagen column (Qiagen, Valencia, CA, USA). Conditioned
media from 293T cells were harvested, concentrated using a
Macrosep centrifugal device (Pall, East Hills, NY, USA)
and stored in aliquots at 4C. Protein expression was con-
ﬁrmed by Western blot in both supernatant and cell lysate
prepared from 2 9 10
5 cells using a standard protocol and
mass spectrometry. An anti-His (C-term)-HRP antibody
(Invitrogen) allowed detection of hHSS1 protein by Wes-
tern blot. Immunoreactive bands were visualized by color-
imetric detection using TMB solution (Invitrogen). The
glycosylation pattern of HSS1 was assessed by treating cell
lysates with PNGase F, Sialidase and O-glycanase.
Detection of hHSS1-mRNA by reverse transcription
(RT)-PCR
Total RNA was isolated from A172 and U87 cell lines
using the RNeasy minikit (Qiagen). The RT-PCR reaction
was carried out by using SuperScrip III One-Step RT-PCR
(Invitrogen) and 1 lg of total RNA. The primers speciﬁc
for HSS1 were: 50-TCCTGCTCTTGCTGATGG-30 (for-
ward); 50-GAGACATAGCCACCAGCTTC-30 (Reverse).
The conditions of the reaction were those suggested by the
manufacturer. A GAPDH mRNA control was also ampli-
ﬁed by PCR according to the manufacturer. PCR products
were then checked via agarose gel electrophoresis.
Selection of stable transfectants
The glioblastoma-derived A172 and U87 cell lines were
transfected as mentioned above, either with pcDNA3.1-
hHSS1 or with pcDNA3.1 empty vector. After 24 h,
800 lgm l
-1 of G-418 (Invitrogen) was added to the cul-
ture. Stable selection was performed for 4-8 weeks and the
stably transfected clones were then expanded and cryo-
preserved in aliquots for further use. The expression of
hHSS1 mRNA was conﬁrmed using RT-PCR.
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123Quantitative proliferation assay
Cell viability was measured by cell counting using trypan
blue exclusion on wild-type (untransfected cells), on
pcDNA3.1 empty vector and pcDNA3.1-hHSS1 clones.
U87 cells (8 9 10
4) were plated in triplicate in 10 cm
plates and incubated at 37C, 5% CO2. After 6 days, the
number of cells was quantiﬁed and the values were
expressed as means. Also, 5 9 10
3 U87 cells were seeded
in septuplicate in 96-well plates and after 3 days of incu-
bation the number of cell aggregates formed was deter-
mined in the central ﬁeld of each well. A172 cells
(8 9 10
4) were plated in triplicate in 10 cm plates and after
7 days the cells were harvested and counted. To test the
plating efﬁciency of A172 cells, 2 9 10
3 A172 cells were
seeded in triplicate in 10-cm plates. After 23 days, cell
colonies were stained for 1 h with 0.001% neutral red
(Sigma-Aldrich, St. Louis, MO, USA) in PBS, after that,
plates were photographed. At least two experiments using
each assay were performed.
Growth inhibition of cells
U87 and A172 wild-type cells, pcDNA3.1 and pcDNA-
hHSS1 cells were seeded at a density of 9 9 10
4/2 ml
medium in 6-well plates in triplicate. Over the course of
8 days, cells were harvested and counted by trypan blue
dye exclusion.
qRT-PCR
For the analysis of hHSS1 expression in brain cancer tissue
we used the TissueScan Brain Cancer Tissue qPCR Array
I—HBRT102 (Origene Technologies, Rockville, MD),
consisting of 48 human brain tissues normalized against
b-actin gene. This array included meningiomas, oligoden-
droglioma and astrocytomas. Normal brain tissue was also
evaluated using Human Brain Tissue qPCR Panel I—
HBRT101 (Origene Technologies), consisting of 24 human
brain tissues normalized against GAPDH gene. qRT-PCR
was performed using SYBR Green PCR master mix (Roche
Diagnostics, Indianapolis, IN) using primers speciﬁc for
hHSS1 (forward 50-CAGCAGGATGGTACCTTGTC-30
and reverse 50-GAGACATAGCCACCAGCTTC-30). Rel-
ative mRNA levels of hHSS1 were calculated using the
LightCycler 480 Relative Quantiﬁcation Software 1.2
(Roche Diagnostics).
Immunocytochemical and immunohistochemical
analysis
hHSS1 was detected in U87 and A172 cells stably
expressing hHSS1 and in formalin-ﬁxed parafﬁn-
embedded tissue sections of glioma tumors. U87 and A172
cells (4 9 10
4 cells) were cultured overnight in 4-well
chamber slides coated with 5 lg/ml ﬁbronectin. Cultures
were ﬁxed in cold methanol for 10 min at -20C. Tissue
sections from four low-grade diffuse astrocytomas (WHO
grade II) and four high-grade astrocytomas (glioblastoma
multiform, WHO grade IV) were incubated in AquaDepar
(Biocare Medical, Concord, CA) reagent at 70C for
10 min. After deparafﬁnization, antigen retrieving was
performed by using Reveal reagent (Biocare Medical). To
block non-speciﬁc protein staining, cultures and sections
were incubated in background sniper (Biocare Medical) for
10 min. hHSS1 was detected by incubation for 2 h with a
custom made rabbit polyclonal anti-hHSS1 serum raised
against synthetic peptide corresponding to amino acids
108–123 using 1:250 and 1:40 dilution for cultures and
tissue sections, respectively (Genescript, Piscataway, NJ).
This step was followed by incubation for 1 h at RT in-
ImmPRESS reagent anti-rabbit Ig Peroxidase (Vector
Laboratories, Burlingame, CA) and 30 min incubation in
ImmPact AEC Peroxidase Substrate (Vector Laboratories).
Slides were further counterstained with hematoxylin.
Negative control included a stain containing all compo-
nents except the hHSS1 primary antibody. The presence of
hHSS1 was visualized by a reddish brown precipitate. The
speciﬁcity of the hHSS1 polyclonal antibody was previ-
ously veriﬁed by Western blot analysis.
Anchorage-independent growth on soft agar
Medium containing U87 cells (8 9 10
4) was mixed with a
0.33% low-melting agarose top suspension, which was then
layered onto a 0.5% bottom agarose. Each assay was per-
formed in triplicate. The plates were incubated at 37C, 5%
CO2 for 23 days; after that, nine ﬁelds of each plate were
photographed and colonies were counted manually.
Intracranial xenograft in immunodeﬁcient mice
Tumorigenicity in vivo was determined by intracranial
injection of U87 glioma-derived cells in male Nu/Nu mice,
age 6 weeks (Charles River Laboratories, Wilmington,
MA, USA). Mice were quarantined for one week before
initiation of the experimental procedure. Initially, mice
were anesthetized with isoﬂurane (FORANE
). The skin
was then cut using a scalpel and retracted for skull expo-
sure. Skulls were punctured with a bone penetrator
approximately 2 mm posterior to Bregma. After skull
puncture, 10 llo fa19 10
6 cell suspension in PBS was
injected with a 100 ll syringe containing a blunt end
needle. The skin was replaced over the skull puncture and
given two stitches. Mice subsequently recovered from the
anesthesia within minutes and became mobile and active.
J Neurooncol (2011) 102:197–211 199
123No apparent ill effects were observed immediately after the
cell injection. Three groups of mice were studied: U87
wild-type cells (N = 8), pcDNA3.1 (N = 5) and
pcDNA3.1-hHSS1 (N = 5). All mice were properly treated
in accordance with guidelines of the Institutional Animal
Care and Use Committee (IACUC) at the BATTS Labo-
ratories facility (Northridge, CA, USA).
Transcript expression proﬁling using microarray
Affymetrix GeneChip Human Gene 1.0 ST Array was used
to obtain transcript expression proﬁles in wild type (non-
transfected), mock stable-transfected (pcDNA3.1 empty
vector) and hHSS1-stable-transfected (pcDNA3.1-hHSS1)
U87 cells. Exponentially growing U87 cells at growth
curve day 4 were harvested by trypsinization and the total
RNA was isolated using the RNeasy minikit (Qiagen).
Further RNA characterization and chip analysis was car-
ried out at the Functional Genomics Core of the City of
Hope (Duarte, CA, USA). Samples were evaluated in
triplicate. Expression values were determined using dChip
(July 9, 2009 build). For glioma tissue microarray, 100
primary gliomas from MD Anderson Hospital patients
(GEO accession #GSE4271) were arranged into Mesen-
chymal, Proneural, and Proliferative subclasses according
to Phillips et al. [8]. hHSS1 probeset expression (Affymetrix
HG-U133 probeset, 224727_at) was then assessed in each
group from MAS5-normalized data, and statistical differ-
ences between groups evaluated using one-tailed student’s
t-test after adjustment for variance.
Statistical analysis
For the proliferation assays, two-tailed Student’s t-tests
were performed to establish the statistical signiﬁcance of
differences between control cells and hHSS1-expressing
cells. Differences among groups in the growth curve
analysis were determined by two-way analysis of variance
(ANOVA) with Tukey’s test for pairwise post-hoc com-
parisons. Survival analysis was performed by the Kaplan–
Meier test. Differences were considered statistically sig-
niﬁcant when P\0.05.
Results
Bioinformatics, cloning and sequencing of HSS1
and HSM1
Using Affymetrix microarray analysis, approximately 900
highly and/or differentially expressed genes were identiﬁed
from three subsets of murine HSC populations [4]. Probe
sets with signiﬁcant expression in the HSC subsets of
unknown gene products were subjected to BLAT analysis
and examined for correspondence to novel in silico pre-
dicted genes. Predicted genes identiﬁed in this manner
were then subjected to analysis for signal peptides using
SignalP (http://www.cbs.dtu.dk/services/SignalP/) and the
absence of a transmembrane domain, using TMHMM
(http://www.cbs.dtu.dk/services/TMHMM/). In this manner,
novel secretable proteins were identiﬁed. Gene expression
corresponding to one probe (96320_at) found in all three
stem cell subsets identiﬁed a downstream untranslated
region of a predicted gene on mouse chromosome 7
(GenScan chr7_6.156) and on human chromosome 19
(GenScan NT_011109.821). The respective mouse and
human gene predictions speciﬁed proteins with 86%
identity to each other, neither of which was existent in the
databank. These mouse and human genes predicted a signal
peptide sequence, but no transmembrane domain, indicat-
ing that the sequences coded for secreted proteins. Both
mouse and human genes were cloned from their respective
mouse and human cDNA libraries via PCR using primers
based upon the gene predictions. The clones were then
sequenced and the predicted sequences were conﬁrmed for
both human and mouse. The secretable form of the gene
was designated HSS1 (Fig. 1a). Additionally, GenBank
entries indicated the presence of a splice variant of HSS1
containing a predicted membrane spanning domain. This
isoform was also ampliﬁed by PCR from the cDNA
libraries, conﬁrmed for both human and mouse and was
designated HSM1, the membrane associated splice variant
of the gene (Fig. 1a). The mouse and human gene ID’s are
69683 and 284361, respectively.
The full-length cDNA sequence of HSS1 consists of
approximately 1.9 kb containing an open reading frame of
789 bp. This sequence was submitted to the NCBI database
and assigned a GenBank accession number, namely
AY761095. The genomic structure of HSS1, as well as
HSM1, is composed of seven exons and six introns cov-
ering a minimum of 6.8 kb (Fig. 1b). The last exon is
alternatively spliced resulting in either HSS1 or HSM1.
The two forms of the gene are encoded at chromosome
19q13.33. Mouse and human HSS1/HSM1 share homology
with ortholog genes in numerous species (Fig. 2a). The
Beijing Genomics Institute Tree Families Database, for
example, includes 45 different species to date as part of the
family (TF314052). Thus, the gene is evolutionarily con-
served across species, phyla and kingdoms, including
mammals, invertebrates and plants.
HSS1 and HSM1 do not have sequence homology
to known naturally occurring proteins
Since HSS1 was identiﬁed solely by bioinformatic analy-
sis, and HSM1 was only one gene out of thousands of
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ous EST or transcriptomic projects, no function could be
attributed a priori to these genes. Towards the aim of
elucidating a function for the proteins encoded by the
HSS1 gene, we searched extensively for homology
between HSS1/HSM1 and proteins with known functions.
We also performed searches to ascertain whether HSS1/
HSM1 contained domains common to a known protein and/
or protein domain family. Using publicly available algo-
rithms to identify protein domains and overall structure, we
failed to ﬁnd any homology with HSS1 or HSM1.
We then used a proprietary algorithm (Eidogen-Sertanty
Inc., Oceanside, CA, USA) based on a 3-D, crystallo-
graphic protein database to align protein sequences of
unknown structure. Interestingly, this search revealed
homology to only one protein in the database. This protein
was a non-natural, computationally designed protein,
designated as TOP7 [9]. From this analysis, we determined
that a region common to HSS1 and HSM1 share structural
homology with TOP7 at the 95% conﬁdence level (Fig. 2b
and c).
HSS1 is a novel secreted protein with a complex
glycosylation pattern
Based on the primary sequence of HSS1, SignalP analysis
showed that HSS1 has a predicted signal peptide, but
according to TMHMM no transmembrane domain. To
further conﬁrm its potential secretory properties, hHSS1
was expressed in 293T cells as a construct containing a
69His tag at its carboxyl terminal. Western blot analysis
using an anti-69His antibody conﬁrmed that HSS1 is a
secreted protein, as it was detected in the supernatant of
transiently transfected 293T cells (Fig. 3a and b). Wild
                  10        20        30        40        50        60
                      |         |         |         |         |         |
hHSM1 MAAASAGATRLLLLLLMAVAAPSRARGSGCRAGTGARGAGAEGREGEACGTVGLLLEHSF
mHSM1        MVAAGAGVTRLLVLLLMVAAAPSRARGSGCRVGASARGTGADGREAEGCGTVALLLEHSF
hHSS1        MAAASAGATRLLLLLLMAVAAPSRARGSGCRAGTGARGAGAEGREGEACGTVGLLLEHSF
mHSS1        MVAAGAGVTRLLVLLLMVAAAPSRARGSGCRVGASARGTGADGREAEGCGTVALLLEHSF
             *.**.**.****:****..************.*:.***:**:***.*.****.*******
                     70        80        90       100       110       120
                      |         |         |         |         |         |
hHSM1        EIDDSANFRKRGSLLWNQQDGTLSLSQRQLSEEERGRLRDVAALNGLYRVRIPRRPGALD
mHSM1        ELGDGANFQKRGLLLWNQQDGTLSATQRQLSEEERGRLRDVAAVNGLYRVRVPRRPGTLD
hHSS1        EIDDSANFRKRGSLLWNQQDGTLSLSQRQLSEEERGRLRDVAALNGLYRVRIPRRPGALD
mHSS1        ELGDGANFQKRGLLLWNQQDGTLSATQRQLSEEERGRLRDVAAVNGLYRVRVPRRPGTLD
             *:.*.***:*** *********** :*****************:*******:*****:**
                    130       140       150       160       170       180
                      |         |         |         |         |         |
hHSM1        GLEAGGYVSSFVPACSLVESHLSDQLTLHVDVAGNVVGVSVVTHPGGCRGHEVEDVDLEL
mHSM1        GSEAGGHVSSFVPACSLVESHLSDQLTLHVDVAGNVVGLSVVVYPGGCRGSEVEDEDLEL
hHSS1        GLEAGGYVSSFVPACSLVESHLSDQLTLHVDVAGNVVGVSVVTHPGGCRGHEVEDVDLEL
mHSS1        GSEAGGHVSSFVPACSLVESHLSDQLTLHVDVAGNVVGLSVVVYPGGCRGSEVEDEDLEL
             * ****:*******************************:***.:****** **** ****
                    190       200       210       220       230       240
                      |         |         |         |         |         |
hHSM1        FNTSVQLQPPTTAPGPETAAFIERLEMEQAQKAKNPQEQKSFFAKYWMYIIP-VVLFLMM
mHSM1  FNTSVQLRPPSTAPGPETAAFIERLEMEQAQKAKNPQEQKSFFAKYWMYIIP-VVLFLMM
hHSS1        FNTSVQLQPPTTAPGPETAAFIERLEMEQAQKAKNPQEQKSFFAKYWHIILGGAVLLTAL
mHSS1        FNTSVQLRPPSTAPGPETAAFIERLEMEQAQKAKNPQEQKSFFAKYWHLILGGAVLLTAL
             *******:**:************************************  *:  .**:  :
                    250       260
                      |         |
hHSM1 SGAPDAGGQGGGGGGGGGGGSGR
mHSM1        SGAPDAGGQGGGGGGGSSR----
hHSS1        R--PATPGPAPPPQEA-------
mHSS1        R--PAAPGPAPAPTEA-------
     * _ * .     .
a
b
HSM1
HSS1
TGA
TGA
Fig. 1 a Protein sequence
alignment for HSS1 and HSM1.
Homology between the two
splice variants in mouse and
human are shown. Identical
residues are indicated by
asterisks. Shaded regions
represent as follows: predicted
signal peptide (light grey);
predicted N-and
O-glycosylation sites at the
amino acid positions 182 and
198 (black box); predicted
transmembrane domain for
hHSM1 (dark grey, note it
contains the ultimate intron–
exon splice boundary which
gives rise to the different forms
of the gene): intron–exon
junctions (bold underlined).
b Intron–exon arrangement of
hHSS1/HSM1. Each HSS1 and
HSM1 contains seven exons.
The last exon differs in both
forms of the protein. Small
arrows indicate PCR primer
sites. TGA: stop codon. The two
forms of the gene are encoded at
locus 19q13.33
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empty vector (data not shown) yielded no protein via
Western blot analysis.
We next wanted to conﬁrm if HSS1 is glycosylated, as
the predicted sequence presented two possible glycosyla-
tion sites at residues 182 and 198 (Fig. 1a) based on
NetNGlyc and NetOGlyc analysis (http://www.cbs.dtu.dk/
services/). Thus, cleavage of HSS1 by glycolytic enzymes
was performed on the cell lysate and supernatants con-
taining HSS1. The apparent molecular weight of ungly-
cosylated HSS1 from analysis of the His tag ladder
(Fig. 3a, lane 1) is approximately 30 kDa (Fig. 3a, lanes
2–5). The theoretical molecular weight of the mature (i.e.
signal peptide cleaved) HSS1 is 24,171 Da. The majority
of the protein in the cell lysate did not appear to be gly-
cosylated as enzyme cleavage did not signiﬁcantly change
the apparent molecular weight. However, for HSS1 that is
secreted and found in the supernatant, cleavage by various
glycolytic enzymes incrementally decreased the apparent
molecular weight of the protein (Fig. 3a, lanes 6–13), thus
suggesting a complex glycosylation pattern.
hHSS1 has a growth inhibitory effect in glioma cells
Following our initial characterization of the physical
properties of HSS1, we next sought to determine a function
for this novel protein. Since Mitelman Breakpoint Data
revealed that hHSS1 is located in a chromosomal region
known to have aberrations or deletions in a variety of
cancers, including various gliomas [10], we ﬁrst investi-
gated whether hHSS1 would affect the malignant proprie-
ties of two well-studied human glioma-derived cell lines,
namely A172 and U87. These glioblastoma cell lines were
chosen for study because previously they were found to
have deletions in a region corresponding to the gene locus
of hHSS1 at 19q13.33 [11]. However, because hHSS1 is
expressed in normal brain tissues [12], we checked whether
these cell lines were expressing hHSS1 by using gene
speciﬁc primers in a one-step RT-PCR reaction. We found
that neither hHSS1 nor hHSM1 mRNA was detectable in
these glioblastoma cell lines (Fig. 4a, lanes 1 and 4).
We then stably transfected A172 and U87 with a con-
struct carrying hHSS1 cDNA (pcDNA3.1-hHSS1) or with
the empty vector as control. The expression of hHSS1
following transfection was conﬁrmed by using RT-PCR.
The results showed that while hHSS1 mRNA was not
detectable in non-transfected wild-type and mock-trans-
fected cells, the selected pcDNA3.1-hHSS1-transfected
clones stably expressed the hHSS1 mRNA (Fig. 4a, lanes 2
and 5).
During the selection of the stable clones, we observed
that the growth of the pcDNA3.1-hHSS1 transfected cells
was dramatically decreased relative to mock-transfected
clones. Thus, cell counting and plating efﬁciency were
performed to evaluate the relative proliferation of clones
transfected with pcDNA3.1-hHSS1 or empty vector. The
results obtained showed that A172- and U87-hHSS1-
expressing glioblastoma cells decreased in cell number by
Fig. 2 a Phylogram of HSS1/
HSM1 protein sequences.
Alignment of HSS1/HSM1
protein sequences from 24
species using ClustalW2 (
http://www.ebi.ac.uk/Tools/
clustalw2/index.html). HSS1/
HSM1 has identiﬁed orthologs
in at least 45 species, of which
24 are shown. b and c Overlay
of TOP7 fold with the HSS1/
HSM1 predicted fold. b Align-
ment of TOP7 (blue) and HSS1/
HSM1 (green) b-sheets (amino
acids 54–159); c alignment of
TOP7 (red) and HSS1/HSM1
(green) alpha-helices. The pre-
dicted probability of these two
domains aligning by chance is
P\0.05
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1233-fold compared to mock-transfected cells (two-tailed
independent Student’s t-test,P\0.001) (Fig. 4b and d).
In addition to reduction in proliferation, expression of the
hHSS1 gene in U87 cells induced morphological changes.
We observed that cell aggregate formation in U87-mock-
transfected cells were discernible (Fig. 4f), probably
reﬂecting loss of contact inhibition in these cells. Cell
aggregates can be viewed as clumps of cells that accumulate
over an initial monolayer. This phenotype in U87 cells was
also reported in a previous study of the Smac gene and its
regulation of tumor cell viability [13]. We next evaluated
the number of cell aggregates formed between hHSS1-
expressing cells and mock-transfected cells. The number of
cell aggregates formed in U87 cells expressing hHSS1 was
5.9 times less relative to mock-transfected cells (two-tailed
independent Student’s t-test, P\0.001) (Fig. 4e). The
number of cells counted in this experiment was 1.32 9 10
5
(pcDNA3.1) and 3.35 9 10
4 (pcDNA3.1-hHSS1) (two-
tailed independent Student’s t-test, P\0.02).
Since A172 cells do not display cell aggregate forma-
tion, we chose to assess the difference in plating efﬁciency
for this cell line as an additional measure of proliferation
and ability to grow at low density. We observed that the
number of colonies formed by A172 cells expressing
hHSS1 was dramatically decreased compared to the mock-
transfected (Fig. 4c), indicating that hHSS1 expression
efﬁciently reduced clonogenic cell survival.
Since we have veriﬁed the expression of hHSS1 in these
cell lines only by mRNA levels, we then checked the
expression of hHSS1 at the protein level by immuno-
chemical analysis. Figure 5 shows immunocytochemical
analysis of U87 (Fig. 5a) and A172 (Fig. 5b) cell lines. No
obvious staining was detectable in non-transfected and
empty-vector transfected U87 cells (Fig. 5a.1–2). Immu-
noreactivity was evident throughout the cells over-
expressing hHSS1, conﬁrming that its transcript in U87 and
A172 (Fig. 5a.3 and 5b.6, respectively) stable cells was
translated into immmocytochemically detectable hHSS1
protein. Conversely, endogenous hHSS1 expression in
some cells was detected in both non-transfected and empty-
vector transfected A172 cells (Fig. 5b.4–5). However, the
A172 hHSS1-transfected cells expressed higher levels of
hHSS1 protein compared to the controls (Fig. 5b.6).
Nuclear staining was observed in A172 cells, suggesting
that hHSS1 may also localize inside the nucleus of these
cells. Thus, hHSS1 could have both intra and extracellular
properties as has been reported for FGFs and epidermal
growth factor (EGF) proteins [14]. Further experiments are
needed to conﬁrm this ﬁnding.
To further examine the growth properties of the hHSS1-
expressing cells, we constructed a growth curve for each
cell line in order to determine whether hHSS1 overex-
pression increased the cell doubling time. The growth rate
was signiﬁcantly affected by hHSS1 overexpression in both
A172 cells [main effect of cell type, F(2, 135) = 98.61,
P\0.001] and U87 cells [main effect of cell type, F(2,
135) = 51.36, P\0.001]. A signiﬁcant growth inhibition
effect was observed after day 3 of experiment for both cell
lines: A172 cells [cell type X day interaction, F(16,
135) = 6.84, P\0.001], U87 cells [cell type X day
interaction, F(16, 135) = 3.45, P\0.001]. Moreover, the
A172 wild-type and mock-transfected cells showed a
doubling time of 27 and 30.5 h, respectively, whereas the
A172 hHSS1-expressing cells showed a doubling time of
40 h (Fig. 6a). Similarly, while U87 wild-type and mock-
transfected cells had a doubling time of 27.4 and 27.6 h,
respectively, the U87 hHSS1-expressing cells had a dou-
bling time of 32.1 h (Fig. 6b). Taken together, these results
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O-Glycanase                     +                          +                      +
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Fig. 3 HSS1 is secreted and multi-glycosylated a Western blot
analysis obtained from 293T cells transfected with the pTT3-hHSS1
construct in serum or serum-free medium. The protein was detected
with anti-His-tag antibody. Samples were also digested with enzymes
that selectively cleave glycosylated proteins. His Tag ladder (lane 1);
denatured cell lysate (lane 2); cell lysate treated with different
enzymes (lanes 3, 4 and 5); denatured supernatant from cells grown in
medium with serum (lane 6); supernatant with serum treated with
different enzymes (lanes 7, 8 and 9); denatured supernatant from cells
grown in serum-free medium (lane 10); supernatant serum-free
treated with different enzymes (lanes 11, 12 and 13). b Western blot
analysis from 293T cell. Serum free supernatant and cell lysate of
293T cells transiently transfected with hHSS1 (lanes 2 and 4,
respectively). Serum free supernatant and cell lysate of wild type
293T cells (lanes 3 and 5, respectively)
J Neurooncol (2011) 102:197–211 203
123indicate that hHSS1, a novel secreted protein in a new
protein class, has a growth-inhibitory effect in malignant
glioma cells.
hHSS1 suppresses the malignant phenotype
of U87 cells in vitro and in vivo
Changes in cell morphology are associated with malignant
transformation in many epithelial tumor cells. Furthermore,
malignantly transformed cells have the ability to grow in the
absence of cell anchorage. To evaluate whether the mor-
phological changes induced by hHSS1 expression (Fig. 4f)
correlate with reduced malignancy in these cells, we com-
pared the ability of U87 cells carrying either the empty
vector or expressing hHSS1 to grow in an anchorage-
independent manner. Results showed that empty vector
control cells formed numerous colonies in soft agar com-
pared to hHSS1-expressing cells (Fig. 7a). Moreover, the
sizes of the colonies of empty vector control cells were
markedly larger than those of cells expressing hHSS1
(Fig. 7b). These results suggest that stable expression of
hHSS1 in U87 cells in which hHSS1 expression previously
had been undetected produces a potentially less malignant
phenotype by restoring the normal cell property of contact
inhibition.
We also evaluated the ability of transplanted U87 cells to
affect survival in immunocompromised mice (A172 cells
were not studied as these cells are not tumorigenic in mice).
Mice implanted with U87 hHSS1-expressing cells survived
signiﬁcantly longer, as compared to those implanted with
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Fig. 4 Growth inhibitory effect of hHSS1 in glioma cells a RT-PCR
analysis of the clones stably transfected with pcDNA3.1-hHSS1 or
pcDNA3.1 empty vector selected for the experiments. A172 and U87
cell lines do not express detectable levels of hHSS1 (or hHSM1)
(lanes 1 and 4, upper panel). PCR product from the stable clones
expressing HSS1 (lanes 2 and 5) and mock-transfected cells (lanes 3
and 6); C1, positive control: 100 ng of pcDNA3.1-hHSS1 plasmid;
C2, negative control: reaction reagent only. b A172 pcDNA3.1 and
pcDNA3.1-hHSS1 transfected cells were seeded (8 9 10
4 cells) and
harvested after 7 days for cell counting by trypan blue exclusion.
c hHSS1 expression suppresses colony formation in A172. A172
pcDNA3.1 and pcDNA3.1-hHSS1 transfected cells were seeded
(2 9 10
3 cells), and after 23 days cells were stained with neutral red.
d U87 pcDNA3.1 and pcDNA3.1-hHSS1 transfected cells were
seeded (8 9 10
4 cells) and harvested after 6 days for cell counting by
trypan blue exclusion. e and f hHSS1 expression decreases U87 cell
aggregation in culture. e U87 cells (5 9 10
3) were seeded in
septuplicate in 96-well plates and incubated for 3 days, and then cell
aggregates were photographed and counted. f hHSS1-expressing cells
presented a much ﬂatter shape while the control cells typically grew
in cell aggregates. All results are presented as grand mean ± SEM of
two independent experiments. * P\0.05, two-tailed independent
Student’s t-test
204 J Neurooncol (2011) 102:197–211
123U87 wild-type cells or cell carrying the empty vector
(78 days vs 34 and 30 days for mock-transfected and wild-
type cells, respectively; P\0.0001; log-rank). This result
suggests that hHSS1 decreases the malignancy of U87 cells
in vivo (Fig. 7c).
hHSS1 alters gene expression proﬁle
in stably-transfected U87 cells
The observed growth inhibitory effect of hHSS1, as well as
its suppression of tumorigenicity in vitro and in vivo, raises
the question of the molecular basis for such phenotypical
changes. Comparative gene expression proﬁling using
Affymetrix GeneChip Human Gene 1.0 ST of wild-type
(non-transfected), mock-stable-transfected (pcDNA3.1
empty vector) and hHSS1-stable-transfected (pcDNA3.1-
hHSS1) U87 cells allowed us to address this question.
Expression proﬁles of U87, mock and hHSS1-transfected
stable cell lines were obtained and compared by two-tailed
paired Student’s t-test. Differential expression due to the
presence of hHSS1 was deﬁned as being statistically sig-
niﬁcant (P\0.05) for the hHSS1-transfected cells com-
pared to both U87 wild-type and the mock transfected
controls with the added criterion that difference in gene
expression between U87 wild-type and mock transfected
cells must not be statistically signiﬁcant (P[0.05). After
these stringent criteria were met, 491 genes were found to
havealteredexpressionlevelsofatleasttwo-fold.Avolcano
plot is shown in Fig. 8. Among these genes were hHSS1
itself which exhibited more than 10-fold increase in
expression in the hHSS1 stable-transfected cells compared
to mock stable-transfected (P = 0.00013) and U87 wild-
type cells (P = 0.00015). The expression levels of hHSS1
between U87 wild-type and the mock stable-transfected
cells was not statistically signiﬁcant (P = 0.39). These
ﬁndings for hHSS1 in the expression proﬁle analysis are
indicativeoftheintegrityoftheanalysis.Overall,166probe-
set deﬁned genes were up-regulated and 325 were down-
Fig. 5 Immunocytochemical
localization of hHSS1 in
cultured glioma-derived cells. a:
1, U87 wild type cells; 2,
pcDNA3.1-transfected U87
cells; 3, pcDNA3.1-hHSS1
transfected U87 cells. Pictures
shown represent cells stained
using anti-rabbit antibody
against hHSS1. b: 4, A172 wild
type cells; 5, pcDNA3.1-
transfected A172 cells; 6,
pcDNA3.1-hHSS1 A172
transfected cells. Red arrows
nuclear staining. Images are
shown in the same
magniﬁcation (2009)
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Fig. 6 hHSS1 expression inhibits A172 and U87 cell doubling. a and
b A172 and U87 cells (wild-type, pcDNA3.1, pcDNA3.1-hHSS1)
were cultured at nine different time points, harvested and counted by
trypan blue exclusion. a hHSS1 signiﬁcantly inhibited the prolifer-
ation of A172 cells after 3 days in culture (*P\0.05, post-ANOVA
pairwise Tukey test). b hHSS1 signiﬁcantly inhibited the proliferation
of U87 cells after 3 days in culture (*P\0.05, post-ANOVA
pairwise Tukey test). Results are shown as grand mean ± SEM of
two independent experiments
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123regulated by at least two-fold demonstrating that hHSS1
expression alters the gene expression proﬁle of U87 cells.
Table 1 displays 8 genes up or down-regulated by hHSS1.
hHSS1 expression in glioma-derived tissues
Next, we examined the expression of hHSS1 by transcript
proﬁling in brain cancer and normal brain. The analysis of
the Brain Cancer Tissue qPCR Array I showed expression
in normal and all tumor grades with a decreased expression
of hHSS1 in WHO grade IV (glioblastoma multiform)
(Fig. 9a). Further, using the Human Brain Tissue qPCR
Panel I hHSS1 expression was found at low levels in
normal tissues from various brain regions, with highest
levels in pituitary tissue (Fig. 9b). Overall, the mRNA level
of hHSS1 relative to the reference genes (GAPDH and
b-actin) was very low in both surveys.
We also evaluated the distribution of hHSS1 in
low-grade diffuse astrocytoma (WHO grade II) and high-
grade astrocytoma (glioblastoma multiforme, WHO grade
IV) using immunohistochemical analysis (Fig. 10). Over-
all, no obvious detection of hHSS1 was found in normal
brain tissue (Fig. 10a and d). High expression levels of
hHSS1 were found in two out of four grade IV astrocyto-
mas (Fig. 10c and f). On the contrary, all four grade II
astrocytomas showed low expression of hHSS1 (Fig. 10b
and e). A minimum perivascular staining was also
observed, mostly in tumor areas. Although the expression
of hHSS1 was predominantly detected in cytoplasm,
nuclear stain was seen focally, as observed in A172 cells.
Moreover, hHSS1 was detected in some but not all tumor
cells. It is important to mention that both sets of primers
used in the qRT-PCR and the antibody used to detect
hHSS1 do not discriminate between the secreted and
membrane bound form of the protein (hHSM1).
hHSS1 expression in glioma molecular subclasses
Since hHSS1 expression was only detectable on a subset of
high-grade gliomas, we considered whether hHSS1 was
differentially up-regulated on functionally distinct molec-
ular subclasses of gliomas. Such subclasses are distin-
guishable by microarray, and include mesenchymal (MES),
proneural (PN), and proliferative (Prolif) subclasses. In
light of the hHSS1 transfection data, which suggested that
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Fig. 7 hHSS1 suppresses anchorage-independent growth and tumor-
igenicity of U87 cells. a U87 cells (pcDNA3.1, pcDNA3.1-hHSS1)
were seeded on top of soft agar in 10 cm plates and the number of
colonies formed in soft agar were counted after 23 days of incubation.
Results are expressed as grand mean ± SEM and are representative
of two independent experiments. * P\0.05, Student’s t-test,
pcDNA3.1-hHSS1 versus U87 wild-type or versus mock-transfected
cells. b Micrograph of U87 colonies grown in soft agar: pcDNA3.1:
mock-transfected cells, pcDNA3.1-hHSS1: cells stably expressing
hHSS1. c Kaplan–Meier analysis of nude mice intracranially injected
with 1 9 10
6 U87 cells expressing hHSS1 (N = 5), U87 wild-type
(N = 8) or mock-transfected cells (N = 5) (Mantel test, P\0.001,).
Survival and tumor growth were monitored daily
Fig. 8 Volcano plot for 491 differentially hHSS1-regulated genes in
U87 stable transfected cells. Values outside -1 and ?1 fold change
and values above negative log P-value 1.3 (P = 0.05) were consid-
ered statistically signiﬁcant down- (left) and up-regulated (right)
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123hHSS1 expression may alter anchorage-dependent growth
and/or cell morphology in vitro, it was particularly
intriguing to consider whether hHSS1 was differentially
expressed on MES subclass gliomas, which up-regulate
genes involved in cell motility and invasiveness. Indeed,
relative up-regulation of hHSS1 expression uniquely
characterized MES subclass gliomas, which expressed
signiﬁcantly more hHSS1 on microarray than either PN or
Prolif subclass gliomas (Fig. 11). Since both MES and
Prolif subclasses include de novo high-grade gliomas,
Table 1 Select genes either up or down-regulated in U87 cells stably expressing hHSS1 as indicated by microarray analysis
Gene hHSS1 vs pcDNA3.1
Fold change
P-value U87-wild type
vs pcDNA3.1
Fold change hHSS1
vs U87-wild type
hHSS1
vs pcDNA3.1
U87-wild type
vs pcDNA3.1
hHSS1* ?11.7 0.00015 0.00013 0.39 1.0
APLN -14 0.0004 0.00003 0.14 1.0
SIK1 ?2.3 0.003 0.00325 0.13 -1.1
ADAMTS1 ?2.9 0.003 0.00203 0.23 1.0
BRCA1 -2.7 0.0002 0.00032 0.12 1.0
BRCA2 -2.6 0.0007 0.00051 0.07 -1.1
CDK2 -2.2 0.0008 0.00064 0.24 1.0
CDK6 -3.1 0.001 0.00050 0.06 -1.1
ASF1B -4.5 0.00005 0.00047 0.46 1.0
P-values were determined by two-tailed paired Student’s t-test. * Ofﬁcial gene symbol for hHSS1 is C19orf63
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Fig. 9 a Expression proﬁles of hHSS1 in brain cancer according to
WHO classiﬁcation. TissueScan Brain Cancer Tissue qRT-PCR Array
I consisting of 48 human brain tissues was used to determine
transcript levels of hHSS1. Data were normalized to b-actin levels.
Error bars displays the SEM. b Expression proﬁles of hHSS1 in
human brain tissues (Human Brain Tissue qPCR Panel I). Data were
normalized to GAPDH levels
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123whereas the PN subclass is largely devoid of these tumors,
this ﬁnding further validates the notion that high hHSS1
expression is conﬁned to a subset of high-grade gliomas
generally, and to the MES subclass in particular.
Discussion
In this study, we have identiﬁed and characterized HSS1, a
novel secreted factor, and its membrane-bound splice
variant, HSM1. Moreover, we report that HSS1 and HSM1
are two members of a novel protein class, and that these
novel proteins have growth inhibitory properties in two
glioblastoma cell lines.
The fact that HSS1 and HSM1 are evolutionarily con-
served across numerous species, phyla and even kingdoms,
including mammals, invertebrates and plants, suggests that
these proteins are of fundamental signiﬁcance in biology.
Yet neither human nor murine HSS1/HSM1 show homol-
ogy to known, naturally occurring proteins, nor do they
contain known functional domains. After using a 3-D
crystallographic protein database to align protein sequen-
ces of unknown structure, it was found that a region
common to HSS1/HSM1 shares structural homology with
TOP-7, which is a non-natural, idealized protein designed
in silico for stability at extreme temperature and pH con-
ditions [9]. It is, therefore, intriguing to speculate whether
HSS1/HSM1 might also exhibit such stability.
High-throughput gene expression analysis of diverse
mouse and human tissue samples has shown that HSS1/
HSM1 is widely expressed in body tissues including brain
[12]. We discovered HSS1/HSM1 by its differential
expression pattern in highly puriﬁed HSCs, thus suggesting
a possible role for this secreted factor in stem cell regula-
tion. Interestingly, in a previous report hHSS1/HSM1 was
shown to be a component of the transcriptome involved in
the signaling networks that control human embryonic stem
cell growth and differentiation [15]. Numerous recent
reports have revealed a connection between stem cell
biology and tumor biology [16]; thus it is possible that
HSS1 may have a role in both areas.
Gene expression data from the CGAP database does
indicate that HSS1 may be involved in numerous cancers,
such as brain, colon, eye, liver, lymph node, mammary
gland, ovary, prostate and skin [17, 18]. Moreover, Mitel-
man breakpoint data for the gene corresponding to HSS1
indicate that its gene locus is a ‘‘hot spot’’ for chromosomal
Fig. 10 Immunohistochemical
analysis of hHSS1 in
representative cases of glioma.
a, d No obvious
immunoreactivity was
detectable in normal brain
tissues). b, e hHSS1
immunoreactivity was low in
low-grade diffuse astrocytoma
(WHO grade II). c, f low and
high expression of hHSS1 in
high-grade astrocytoma
(glioblastoma multiforme,
WHO grade IV). Sections were
stained using anti-rabbit
antibody against hHSS1. Images
are shown in the same
magniﬁcation (2009)
0
500
1000
1500
2000
2500
3000
3500
4000
MES PN Prolif
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
u
n
i
t
s
P = 0.005
P = 0.015
Fig. 11 Expression of hHSS1 by glioma molecular subclasses.
Expression data from 100 primary gliomas from MD Anderson
Hospital patients (GEO accession #GSE4271) were arranged into
Mesenchymal (MES; n = 35), Proneural (PN; n = 37), and Prolif-
erative (Prolif; n = 28) groups according to Phillips et al. [8]. hHSS1
probeset (Affymetrix HG-U133, 224727_at) expression was assessed
in each group from MAS5-normalized data. Statistical differences
between groups was evaluated using one-tailed t-test after adjustment
for variance, with P values as shown. Mean expression ± SEM was
as follows: MES, 3057 ± 211; PN, 2408 ± 125; Prolif, 2345 ± 244
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123aberrations implicated in a variety of human cancers [10],
thereby suggesting a broad role for hHSS1 in cancer.
Upon the discovery of HSS1, only two facts guided the
search for a function for this novel protein. First, HSS1 was
highly expressed in HSCs and its human genetic locus was
at 19q13.33. Since chromosome 19q also harbors at least
one gene important for normal glial development and
growth regulation as well as for the development of diffuse
gliomas [5, 6, 19], we chose to ﬁrst investigate a possible
role for hHSS1 in glioma. Another suggestive link between
hHSS1 and glioma was that the common region for fre-
quent deletions in glioma involves the 19q13.2-13.4 posi-
tion [5]. This position is situated distal to the D19S178
marker and proximal to the D19S180 marker [5, 20], a
region which includes the hHSS1 gene (Fig. 12).
Although chromosome 19q may harbor a potential pan-
glioma tumor suppressor gene, to date, the glioma sup-
pressor genes in this chromosome region remain elusive.
Thus, we investigated the effect of ectopic expression of
hHSS1 on the malignant properties of glioma-derived cells.
The results showed that hHSS1 expression dramatically
decreased the growth rate of U87 and A172 glioma-derived
cells. In addition, stable expression of hHSS1 in A172 cells
strongly inhibited their capacity to grow in low density
compared with control cells, which might express endog-
enous hHSS1 at low levels. The ability to reduce their
growth in low density was also observed for U87 cells
stably transfected with hHSS1 (data not shown).
It was also striking that U87 cells expressing hHSS1
formed 5.9 times fewer cell aggregates compared to mock-
transfected cells. The results also indicate that the expres-
sion of hHSS1 may promote growth suppression in U87
cells involving a decrease in growth rate following a
decrease in the cell doubling-time. Further experiments are
needed to clarify the mechanism by which hHSS1 sup-
presses the growth of U87 and A172 cells.
The expression of hHSS1 also signiﬁcantly attenuated
the colony-forming ability of U87 cells in soft agar matrix,
further indicating a possible involvement of hHSS1 in
restoration of contact inhibition. In addition, mice injected
with U87 cells expressing hHSS1 showed on average
greater than 2-fold extension of their life span, indicating
that hHSS1 affected the malignant phenotype of glioma-
derived cells.
Comparative expression proﬁling results using Affyme-
trix gene chip demonstrated that the stable expression of
hHSS1 in U87 cells signiﬁcantly altered its gene expression
proﬁle. A substantial number of genes were observed to be
either up- or down-regulated by at least two-fold. Pre-
sumably genes among this population contribute to the
phenotype observed for the hHSS1 stable-transfected cells.
Of immediate note and worth mention are the following
observations. Apelin was seen as one of the most down-
regulated genes in hHSS1-overexpressing cells with an
approximate 14-fold decrease in expression. Apelin
expression has been observed to be highly up-regulated in
the microvasculature in brain tumors. In particular, apelin
has been shown to be needed for intersomitic vessel
angiogenesis and the promotion of angiogenesis in brain
tumors [21]. The fact that the expression of apelin is highly
down-regulated in the hHSS1-overexpressing cells is con-
sistent with the observed in vivo results where tumor
growth was greatly suppressed, thereby leading to a sig-
niﬁcant increase in survival. It is of further interest that
SIK1 (salt inducible kinase 1) gene was among the highly
up-regulated genes. This ﬁnding is intriguing in that SIK1
has been shown to be a regulator of anoikis and a sup-
pressor of metastasis [22]. Metastatic tumors generally will
avoid anoikis despite loss of adherence. In the case of
hHSS1 stable-transfected cells, the increase in SIK1 would
presumably correspond to an increase in anoikis and
decrease in metastasis, thus suppressing tumor growth and
spread. The ADAMTS1 gene was also up-regulated in
hHSS1 stable-transfected cells. This metalloproteinase has
been found to suppress tumorigenicity and metastasis in
model systems [23, 24]. Further changes in gene expression
Fig. 12 Mapped position of the putative glioma tumor suppressor at
chromosome 19q region a Chromosome 19 (q13.31–q13.43), region
of the putative glioma tumor suppressor suggested by von Deimling
et al. [20], between the markers D19S178 and D19S180 (red
rectangle). This region includes the hHSS1 gene (C19orf63).
b Chromosome 19 (q13.32–q13.33), region of the putative glioma
tumor suppressor gene narrowed by Rubio et al. [5]( smaller red
rectangle). This region is situated between the loci APOC2 and HRC,
which excludes the hHSS1 gene. c Chromosome 19q13.33, red bar
represent the genome location of hHSS1. The UCSC database was
used as reference (http://genome.ucsc.edu/cgi-bin/hgGateway)
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123to note in hHSS1-overexpressing cells include down-reg-
ulation of both BRCA1 and BRCA2 genes, a number of
cell cycle associated genes (e.g. CDK2, CDK6), tubulins
and the histone chaperone gene ASF1B along with a
number of other histone genes. Validation of these and
other genes of interest are underway.
In tumor tissues, the overall expression levels of hHSS1
were low and variable and the analysis of more tumor
samples are needed to form a deﬁnite conclusion. However
it is interesting to note that hHSS1 expression was
observed minimally in all 4 low-grade diffuse astrocytomas
(WHO grade II) analyzed, while half of the high-grade
astrocytomas (glioblastoma multiforme, WHO grade IV)
exhibited increased expression. This ﬁnding is in agree-
ment with previous reports suggesting a correlation
between low-grade gliomas and deletion of 19q13 region
[25]; this deletion is less common in high-grade gliomas.
Moreover, the notion that only a subset of high-grade gli-
omas over-expresses hHSS1 was further supported by
microarray data, which indicated that MES subclass glio-
mas exclusively up-regulated hHSS1. This ﬁnding is
intriguing in light of transfectant data that suggested stable
expression of hHSS1 alters glioma anchorage-independent
growth and morphology, thus implicating a functional role
of hHSS1 in glioma growth and/or invasiveness. Further
studies are required to test this hypothesis and to clarify if
the high-expression of hHSS1 in high-grade gliomas are
due to (a) mutations in hHSS1 itself; (b) mutations in
downstream effectors of hHSS1; (c) interruption of path-
ways not related to hHSS1; and (d) detection of the splice
variant of hHSS1 (hHSM1).
Previous studies have suggested a few candidate glioma
tumor suppressor genes in a 150-kilobase region that maps
to 19q13.33 [5, 6]. It has been reported that alterations in
GLTSCR1 are associated with the development and
progression of oligodendroglioma [26]. Furthermore,
p190RhoGAP, a gene located at 19q13.3, regulates critical
components of PDGF oncogenesis and can act as a tumor
suppressor in PDGF-induced gliomas by down regulation
of Rho activity [27]. Our present studies suggest that
hHSS1 is another factor located at 19q13.33 that is
involved in suppression of glioma growth.
In conclusion, our data show that (i) hHSS1 is a novel,
previously uncharacterized, secreted factor located within a
previously deﬁned candidate tumor suppressor gene region
at 19q13.33 and (ii) hHSS1 is implicated in the growth
inhibition and restoration of the normal contact inhibition
properties of glioma-derived cells. Thus, the discovery of
the novel secreted protein, hHSS1, and the elucidation of
its functional role in the inhibition of glioma could provide
the opportunity to develop novel treatment strategies for
malignant gliomas.
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